---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-102324"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:12:47.678244+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Organon CEO resigns after probe finds improper Nexplanon wholesaler sales; Morrissey named interim CEO

## Summary
- Kevin Ali resigned as CEO and Board member; no severance or equity retirement benefits.
- Audit Committee investigation found wholesalers asked to buy excess Nexplanon in 7 quarters; sales <1% of annual revenue but helped meet guidance.
- Joseph Morrissey appointed Interim CEO; salary raised to $1M, bonus target 100%, LTI target $4M, one-time RSU grant of $1M.
- Carrie Cox named Executive Chair; Robert Essner Lead Independent Director; Helene Gayle chairs Talent Committee.
- No restatement of prior financials; 2024 internal control opinion withdrawn; Head of US Commercial & Government Affairs terminated.

## SEC filing metadata
- accession: 0001104659-25-102324
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465925102324/0001104659-25-102324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465925102324/tm2529513d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-102324
- JSON: https://secwatch.observer/filing/0001104659-25-102324.json
- Plain text: https://secwatch.observer/filing/0001104659-25-102324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.